BEDFORD, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the peer-reviewed publication of data showing that AAVHSC16, one ...
BEDFORD, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that it has completed a review of its business, and the Board of ...
Homology Medicines has found a source of fresh funding. With its share price in the doldrums and its cash runway nearing its final year, Homology is offloading manufacturing assets through a joint ...
Homology Medicines has joined the growing list of biotechs hitting a wall in 2023, with the gene therapy-focused company blaming the “current financing environment” for the move to lay off 87% of ...
This press release is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor ...
Gene editing company Homology Medicines (NASDAQ:FIXX) added ~23% pre-market Friday after announcing that the company intends to evaluate strategic alternatives, including potential partnerships, a ...
The field of human genetics is discovering disease-causing mutations at a rapid pace. These mutations drive thousands of rare, debilitating and fatal disorders. While some treatments are available to ...
In recent years, CRISPR-Cas9 genome editing has enjoyed spectacular success because it combines flexibility and usability. The Cas9 nuclease need only be loaded with a guide RNA to direct it to almost ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results